<i>In Silico</i>Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers
Chuipu Cai(Guangzhou University of Chinese Medicine), Feixiong Cheng(Cleveland Clinic Lerner College of Medicine), Jiansong Fang(Guangzhou University of Chinese Medicine), Javid J. Moslehi(Cardiovascular Institute of the South), Qi Wang(Hebei Medical University), Huixiao Hong(United States Food and Drug Administration), Pengfei Guo(Guangzhou University of Chinese Medicine)
Cited by 55
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study
|The Lancet Public Health|2020|1.8k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Telomere dysfunction induces metabolic and mitochondrial compromise
|Nature|2011|1.3k